Published in Transplantation on February 15, 2010
Pros and cons for C4d as a biomarker. Kidney Int (2012) 2.03
A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J Exp Med (2013) 1.47
Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients. Transfusion (2014) 1.38
Targeting B cells and antibody in transplantation. Am J Transplant (2011) 1.34
Antibody-mediated rejection in kidney transplantation: a review. J Transplant (2012) 1.12
Novel immunosuppressive agents in kidney transplantation. World J Transplant (2013) 0.96
Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant (2012) 0.95
Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation (2012) 0.92
End-stage renal disease in 2010: Innovative approaches to improve outcomes in transplantation. Nat Rev Nephrol (2011) 0.89
Treatment options and strategies for antibody mediated rejection after renal transplantation. Semin Immunol (2011) 0.81
Current state of renal transplant immunosuppression: Present and future. World J Transplant (2012) 0.81
Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes. J Transplant (2012) 0.81
The Tao of myeloma. Blood (2014) 0.80
The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation (2016) 0.79
Antibody-mediated rejection: an evolving entity in heart transplantation. J Transplant (2012) 0.79
Bortezomib in kidney transplantation. J Transplant (2010) 0.78
Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach. J Artif Organs (2010) 0.78
Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection. Transplantation (2012) 0.78
Modern approaches to incompatible kidney transplantation. World J Nephrol (2015) 0.78
Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management. Curr Transplant Rep (2014) 0.76
32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody. Transplantation (2016) 0.76
Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study. Xenotransplantation (2013) 0.75
Biologics in renal transplantation. Pediatr Nephrol (2014) 0.75
Antibody desensitization therapy in highly sensitized lung transplant candidates. Am J Transplant (2014) 0.75
Alemtuzumab induction in renal transplantation. N Engl J Med (2011) 4.13
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum (2004) 3.35
How deceased donor transplantation is impacting a decline in commercial transplantation-the Tamil Nadu experience. Transplantation (2012) 2.14
Donors with central nervous system malignancies: are they truly safe? Transplantation (2003) 2.12
Malignancy after transplantation. Transplantation (2005) 1.92
Decreased cumulative access survival in arteriovenous fistulas requiring interventions to promote maturation. Clin J Am Soc Nephrol (2010) 1.75
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation (2008) 1.66
Comparing living donor and deceased donor liver transplantation: A matched national analysis from 2007 to 2012. Liver Transpl (2014) 1.63
Anatomic configuration affects the flow rate and diameter of porcine arteriovenous fistulae. Kidney Int (2012) 1.58
Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol (2006) 1.58
Severe venous neointimal hyperplasia prior to dialysis access surgery. Nephrol Dial Transplant (2011) 1.54
Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis (2009) 1.52
Photoinstability of S-nitrosothiols during sampling of whole blood: a likely source of error and variability in S-nitrosothiol measurements. Clin Chem (2008) 1.48
Hand-assisted laparoscopic living-donor nephrectomy as an alternative to traditional laparoscopic living-donor nephrectomy. Am J Transplant (2002) 1.44
Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation (2002) 1.43
Temporary silastic mesh closure for adult liver transplantation: a safe alternative for the difficult abdomen. Liver Transpl (2007) 1.40
Early arteriovenous fistula failure: a logical proposal for when and how to intervene. Clin J Am Soc Nephrol (2005) 1.32
An initial experience and evolution of laparoscopic hepatic resectional surgery. Surgery (2004) 1.26
De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation (2009) 1.25
Laser capture microdissection-microarray analysis of focal segmental glomerulosclerosis glomeruli. Nephron Exp Nephrol (2007) 1.24
Venous stenosis in a pig arteriovenous fistula model--anatomy, mechanisms and cellular phenotypes. Nephrol Dial Transplant (2007) 1.22
West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation (2004) 1.18
Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. Transplantation (2014) 1.16
Donor transmitted malignancies. Ann Transplant (2004) 1.13
Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. Kidney Int (2002) 1.12
Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int (2012) 1.10
Vascular access in haemodialysis: strengthening the Achilles' heel. Nat Rev Nephrol (2013) 1.09
Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study. J Vasc Surg (2009) 1.07
Laparoscopic donor nephrectomy vs. open live donor nephrectomy: a quality of life and functional study. Clin Transplant (2005) 1.07
Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-inhibiting activity of X-linked inhibitor of apoptosis protein. J Biol Chem (2003) 1.06
Deletion of the pH sensor GPR4 decreases renal acid excretion. J Am Soc Nephrol (2010) 1.04
Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice. Am J Physiol Regul Integr Comp Physiol (2006) 1.03
Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation (2013) 1.03
Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation (2002) 1.03
A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant (2005) 1.02
Clinical epidemiology of arteriovenous fistula in 2007. J Nephrol (2007) 1.02
Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant (2008) 1.01
The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol (2003) 1.00
Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant (2009) 1.00
Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. Nephrol Dial Transplant (2006) 1.00
Fostering innovation, advancing patient safety: the kidney health initiative. Clin J Am Soc Nephrol (2013) 1.00
A multi-center, dose-escalation study of human type I pancreatic elastase (PRT-201) administered after arteriovenous fistula creation. J Vasc Access (2012) 0.98
Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation (2011) 0.98
Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant (2008) 0.98
Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol (2011) 0.97
Laparoscopic liver resection. J Am Coll Surg (2005) 0.95
Deletion of the chloride transporter slc26a7 causes distal renal tubular acidosis and impairs gastric acid secretion. J Biol Chem (2009) 0.95
Hemodynamic wall shear stress profiles influence the magnitude and pattern of stenosis in a pig AV fistula. Kidney Int (2008) 0.95
Targeting the ubiquitin+proteasome system in solid tumors. Semin Hematol (2012) 0.95
Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation. Transplantation (2011) 0.95
Gastric bypass in morbidly obese patients with chronic renal failure and kidney transplant. Transplantation (2004) 0.94
Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant (2005) 0.94
Preexisting venous calcification prior to dialysis vascular access surgery. Semin Dial (2012) 0.94
Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation (2013) 0.92
Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation (2012) 0.92
Characteristics and survival patterns of solid organ transplant patients developing de novo colon and rectal cancer. Dis Colon Rectum (2004) 0.92
Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients. Transplantation (2014) 0.91
Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. J Am Coll Surg (2010) 0.90
Basic and clinical research in polyomavirus nephropathy. Exp Clin Transplant (2004) 0.90
Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant (2005) 0.90
Composite tissue allotransplantation: a review of relevant immunological issues for plastic surgeons. J Plast Reconstr Aesthet Surg (2008) 0.90
BKV and JCV large T antigen-specific CD8+ T cell response in HLA A*0201+ kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy. J Clin Virol (2008) 0.90
Desensitization in kidney transplantation: review and future perspectives. Clin Transplant (2014) 0.90
Spermidine/spermine-N1-acetyltransferase ablation protects against liver and kidney ischemia-reperfusion injury in mice. Am J Physiol Gastrointest Liver Physiol (2009) 0.90
Surgical salvage of the autogenous arteriovenous fistula (AVF). J Nephrol (2007) 0.89
Rare subtypes of BK virus are viable and frequently detected in renal transplant recipients with BK virus-associated nephropathy. Virology (2010) 0.89
Alternative medicine use in dialysis patients: potential for good and bad! Nephron Clin Pract (2006) 0.88
YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study. Clin Transplant (2010) 0.88